When should icodextrin be started to improve atherosclerosis in peritoneal dialysis patients? 2013

Takeyuki Hiramatsu, and Takahiro Hayasaki, and Akinori Hobo, and Shinji Furuta, and Koki Kabu, and Yukio Tonozuka, and Yoshiyasu Iida
Department of Nephrology, Aichi Welfare Cooperative Agricultural, Tokyo, Japan. t-hiramatsu@konan.jaaikosei.or.jp

Icodextrin-based peritoneal dialysis (PD) has many advantages over glucose-based PD. The present study aimed to investigate when icodextrin should be started for better management of cardiovascular status (as defined by echocardiography findings) and residual renal function (RRF). We retrospectively analyzed 40 patients treated with continuous ambulatory PD or automated PD. The patients were divided into these groups: Group A: started icodextrin within 2 weeks after PD onset. Group B: started icodextrin 1 year after PD onset. Group C: started icodextrin 2 years after PD onset. Group D: never used icodextrin during the study period. At the start of PD, we observed no significant difference in left ventricular mass index (LVMI) or urine volume (UV) between the groups. At 4 years, LVMI and UV were both significantly improved in group A compared with group D. The amelioration in LVMI was negatively associated with phosphate elimination. Our study showed that icodextrin preserved RRF and ameliorated left ventricular hypertrophy. Moreover, the timing of icodextrin introduction in PD patients influenced the clinical effects, including progression of cardiac hypertrophy and RRF.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010530 Peritoneal Dialysis Dialysis fluid being introduced into and removed from the peritoneal cavity as either a continuous or an intermittent procedure. Dialyses, Peritoneal,Dialysis, Peritoneal,Peritoneal Dialyses
D003324 Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause. Arteriosclerosis, Coronary,Atherosclerosis, Coronary,Coronary Arteriosclerosis,Coronary Atherosclerosis,Left Main Coronary Artery Disease,Left Main Coronary Disease,Left Main Disease,Arterioscleroses, Coronary,Artery Disease, Coronary,Artery Diseases, Coronary,Atheroscleroses, Coronary,Coronary Arterioscleroses,Coronary Artery Diseases,Coronary Atheroscleroses,Left Main Diseases
D005260 Female Females
D005936 Glucans Polysaccharides composed of repeating glucose units. They can consist of branched or unbranched chains in any linkages. Glucan,Polyglucose,Polyglucoses,Glucan (BO),Glucose Polymer,Polycose,Polymer, Glucose
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077607 Icodextrin A glucan that is structurally related to maltodextrin, with more than 85% of its molecules having molecular weights between 1640 and 45 000 Daltons (Da), and a weight-average molecular weight of about 20 000 Da; it is used in dialysis fluids as an alternative to glucose-based solutions, and to reduce adhesions after gynecological or abdominal surgery. It has also been used as a vehicle for drugs given via the peritoneal cavity. Extraneal,Icodial

Related Publications

Takeyuki Hiramatsu, and Takahiro Hayasaki, and Akinori Hobo, and Shinji Furuta, and Koki Kabu, and Yukio Tonozuka, and Yoshiyasu Iida
January 2013, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis,
Takeyuki Hiramatsu, and Takahiro Hayasaki, and Akinori Hobo, and Shinji Furuta, and Koki Kabu, and Yukio Tonozuka, and Yoshiyasu Iida
January 1989, Contributions to nephrology,
Takeyuki Hiramatsu, and Takahiro Hayasaki, and Akinori Hobo, and Shinji Furuta, and Koki Kabu, and Yukio Tonozuka, and Yoshiyasu Iida
December 1975, Geriatrics,
Takeyuki Hiramatsu, and Takahiro Hayasaki, and Akinori Hobo, and Shinji Furuta, and Koki Kabu, and Yukio Tonozuka, and Yoshiyasu Iida
November 2010, Zhonghua yi xue za zhi,
Takeyuki Hiramatsu, and Takahiro Hayasaki, and Akinori Hobo, and Shinji Furuta, and Koki Kabu, and Yukio Tonozuka, and Yoshiyasu Iida
October 1986, Lancet (London, England),
Takeyuki Hiramatsu, and Takahiro Hayasaki, and Akinori Hobo, and Shinji Furuta, and Koki Kabu, and Yukio Tonozuka, and Yoshiyasu Iida
January 2018, Kidney international reports,
Takeyuki Hiramatsu, and Takahiro Hayasaki, and Akinori Hobo, and Shinji Furuta, and Koki Kabu, and Yukio Tonozuka, and Yoshiyasu Iida
May 1947, Dental survey,
Takeyuki Hiramatsu, and Takahiro Hayasaki, and Akinori Hobo, and Shinji Furuta, and Koki Kabu, and Yukio Tonozuka, and Yoshiyasu Iida
August 2001, Praxis,
Takeyuki Hiramatsu, and Takahiro Hayasaki, and Akinori Hobo, and Shinji Furuta, and Koki Kabu, and Yukio Tonozuka, and Yoshiyasu Iida
October 2002, Kidney international. Supplement,
Takeyuki Hiramatsu, and Takahiro Hayasaki, and Akinori Hobo, and Shinji Furuta, and Koki Kabu, and Yukio Tonozuka, and Yoshiyasu Iida
August 2023, Clinical journal of the American Society of Nephrology : CJASN,
Copied contents to your clipboard!